Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 May:167:175-176.
doi: 10.1016/j.ejca.2022.02.032. Epub 2022 Mar 15.

Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients

Giorgio Patelli  1 , Arianna Pani  2 , Alessio Amatu  3 , Francesco Scaglione  2 , Andrea Sartore-Bianchi  4
Affiliations
Comment

Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients

Giorgio Patelli et al. Eur J Cancer. 2022 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Comment on

References

    1. Amatu A., et al. Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment. Eur. J. Cancer Oxf. Engl. 1990. 2021;163:16–25. - PMC - PubMed
    1. Pani A., et al. Antibody response to BNT162b vaccine is almost universal in health care workers. Results from the RENAISSANCE study: REsponse to BNT162b2 COVID-19 vacciNe - short and long term Immune reSponSe evAluatioN in healthCare workErs. Mayo Clin Proc. 2021 doi: 10.1016/j.mayocp.2021.08.013. - DOI - PMC - PubMed
    1. Ligumsky H., et al. Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer. Lancet Oncol. 2021 doi: 10.1016/S1470-2045(21)00715-4. S1470-2045(21)00715–4. - DOI - PMC - PubMed
    1. Shapiro L.C., et al. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell. 2022;40:3–5. - PMC - PubMed